These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

560 related articles for article (PubMed ID: 29202477)

  • 1. CRISPR-Cas9 screen reveals a MYCN-amplified neuroblastoma dependency on EZH2.
    Chen L; Alexe G; Dharia NV; Ross L; Iniguez AB; Conway AS; Wang EJ; Veschi V; Lam N; Qi J; Gustafson WC; Nasholm N; Vazquez F; Weir BA; Cowley GS; Ali LD; Pantel S; Jiang G; Harrington WF; Lee Y; Goodale A; Lubonja R; Krill-Burger JM; Meyers RM; Tsherniak A; Root DE; Bradner JE; Golub TR; Roberts CW; Hahn WC; Weiss WA; Thiele CJ; Stegmaier K
    J Clin Invest; 2018 Jan; 128(1):446-462. PubMed ID: 29202477
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Druggable epigenetic suppression of interferon-induced chemokine expression linked to
    Seier JA; Reinhardt J; Saraf K; Ng SS; Layer JP; Corvino D; Althoff K; Giordano FA; Schramm A; Fischer M; Hölzel M
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34016720
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective gene dependencies in MYCN-amplified neuroblastoma include the core transcriptional regulatory circuitry.
    Durbin AD; Zimmerman MW; Dharia NV; Abraham BJ; Iniguez AB; Weichert-Leahey N; He S; Krill-Burger JM; Root DE; Vazquez F; Tsherniak A; Hahn WC; Golub TR; Young RA; Look AT; Stegmaier K
    Nat Genet; 2018 Sep; 50(9):1240-1246. PubMed ID: 30127528
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Functional MYCN signature predicts outcome of neuroblastoma irrespective of MYCN amplification.
    Valentijn LJ; Koster J; Haneveld F; Aissa RA; van Sluis P; Broekmans ME; Molenaar JJ; van Nes J; Versteeg R
    Proc Natl Acad Sci U S A; 2012 Nov; 109(47):19190-5. PubMed ID: 23091029
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Physical interaction between MYCN oncogene and polycomb repressive complex 2 (PRC2) in neuroblastoma: functional and therapeutic implications.
    Corvetta D; Chayka O; Gherardi S; D'Acunto CW; Cantilena S; Valli E; Piotrowska I; Perini G; Sala A
    J Biol Chem; 2013 Mar; 288(12):8332-8341. PubMed ID: 23362253
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biological effects of induced MYCN hyper-expression in MYCN-amplified neuroblastomas.
    Torres J; Regan PL; Edo R; Leonhardt P; Jeng EI; Rappaport EF; Ikegaki N; Tang XX
    Int J Oncol; 2010 Oct; 37(4):983-91. PubMed ID: 20811720
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MYCN contributes to the malignant characteristics of erythroleukemia through EZH2-mediated epigenetic repression of p21.
    Liu L; Xu F; Chang CK; He Q; Wu LY; Zhang Z; Li X
    Cell Death Dis; 2017 Oct; 8(10):e3126. PubMed ID: 29022893
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The synergy of BET inhibitors with aurora A kinase inhibitors in MYCN-amplified neuroblastoma is heightened with functional TP53.
    Yi JS; Sias-Garcia O; Nasholm N; Hu X; Iniguez AB; Hall MD; Davis M; Guha R; Moreno-Smith M; Barbieri E; Duong K; Koach J; Qi J; Bradner JE; Stegmaier K; Weiss WA; Gustafson WC
    Neoplasia; 2021 Jun; 23(6):624-633. PubMed ID: 34107377
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MYCN is amplified during S phase, and c‑myb is involved in controlling MYCN expression and amplification in MYCN‑amplified neuroblastoma cell lines.
    Aygun N; Altungoz O
    Mol Med Rep; 2019 Jan; 19(1):345-361. PubMed ID: 30483774
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GRHL1 acts as tumor suppressor in neuroblastoma and is negatively regulated by MYCN and HDAC3.
    Fabian J; Lodrini M; Oehme I; Schier MC; Thole TM; Hielscher T; Kopp-Schneider A; Opitz L; Capper D; von Deimling A; Wiegand I; Milde T; Mahlknecht U; Westermann F; Popanda O; Roels F; Hero B; Berthold F; Fischer M; Kulozik AE; Witt O; Deubzer HE
    Cancer Res; 2014 May; 74(9):2604-16. PubMed ID: 24419085
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MYCN Amplification Is Associated with Reduced Expression of Genes Encoding γ-Secretase Complex and NOTCH Signaling Components in Neuroblastoma.
    Agarwal P; Glowacka A; Mahmoud L; Bazzar W; Larsson LG; Alzrigat M
    Int J Mol Sci; 2023 May; 24(9):. PubMed ID: 37175848
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The PRC2 molecule EED is a target of epigenetic therapy for neuroblastoma.
    Shaliman D; Takenobu H; Sugino RP; Ohira M; Kamijo T
    Eur J Cell Biol; 2022; 101(3):151238. PubMed ID: 35636260
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Review: Targeting EZH2 in neuroblastoma.
    Gao J; Fosbrook C; Gibson J; Underwood TJ; Gray JC; Walters ZS
    Cancer Treat Rev; 2023 Sep; 119():102600. PubMed ID: 37467626
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TAp63 represses transcription of MYCN/NCYM gene and its high levels of expression are associated with favorable outcome in neuroblastoma.
    Suenaga Y; Yamamoto M; Sakuma T; Sasada M; Fukai F; Ohira M; Yamaguchi Y; Yamamoto T; Ando K; Ozaki T; Nakagawara A
    Biochem Biophys Res Commun; 2019 Oct; 518(2):311-318. PubMed ID: 31427086
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MYCN and PRC1 cooperatively repress docosahexaenoic acid synthesis in neuroblastoma via ELOVL2.
    Ding Y; Yang J; Ma Y; Yao T; Chen X; Ge S; Wang L; Fan X
    J Exp Clin Cancer Res; 2019 Dec; 38(1):498. PubMed ID: 31856871
    [TBL] [Abstract][Full Text] [Related]  

  • 16. p19-INK4d inhibits neuroblastoma cell growth, induces differentiation and is hypermethylated and downregulated in MYCN-amplified neuroblastomas.
    Dreidax D; Bannert S; Henrich KO; Schröder C; Bender S; Oakes CC; Lindner S; Schulte JH; Duffy D; Schwarzl T; Saadati M; Ehemann V; Benner A; Pfister S; Fischer M; Westermann F
    Hum Mol Genet; 2014 Dec; 23(25):6826-37. PubMed ID: 25104850
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Distinct transcriptional MYCN/c-MYC activities are associated with spontaneous regression or malignant progression in neuroblastomas.
    Westermann F; Muth D; Benner A; Bauer T; Henrich KO; Oberthuer A; Brors B; Beissbarth T; Vandesompele J; Pattyn F; Hero B; König R; Fischer M; Schwab M
    Genome Biol; 2008 Oct; 9(10):R150. PubMed ID: 18851746
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ID2 expression is not associated with MYCN amplification or expression in human neuroblastomas.
    Wang Q; Hii G; Shusterman S; Mosse Y; Winter CL; Guo C; Zhao H; Rappaport E; Hogarty MD; Maris JM
    Cancer Res; 2003 Apr; 63(7):1631-5. PubMed ID: 12670915
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SMAD9-MYCN positive feedback loop represents a unique dependency for MYCN-amplified neuroblastoma.
    Tan K; Mo J; Li M; Dong Y; Han Y; Sun X; Ma Y; Zhu K; Wu W; Lu L; Liu J; Zhao K; Zhang L; Tang Y; Lv Z
    J Exp Clin Cancer Res; 2022 Dec; 41(1):352. PubMed ID: 36539767
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MYCN and MYC regulate tumor proliferation and tumorigenesis directly through BMI1 in human neuroblastomas.
    Huang R; Cheung NK; Vider J; Cheung IY; Gerald WL; Tickoo SK; Holland EC; Blasberg RG
    FASEB J; 2011 Dec; 25(12):4138-49. PubMed ID: 21856782
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.